On July 31, 2023, Aldeyra Therapeutics, Inc. was sued for violations of the federal securities laws in the United States District Court for the District of Massachusetts on behalf of investors who purchased or otherwise acquired Aldeyra securities between March 17, 2022 and June 20, 2023, both dates inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.